Methylphenidate enhances neural stem cell differentiation

Journal of Molecular Psychiatry

Edna Grünblatt¹  Hiroki Ozawa³  Peter Riederer⁴  Takatoshi Mori³  Jasmin Bartl² 

[1] Neuroscience Center Zurich, University of Zurich and ETH Zurich, Switzerland;Hospital of Child and Adolescent Psychiatry, University of Zurich, Winterthurerstr. 180, Room L84/86, 8057, Zurich, Switzerland;Division of Neuropsychiatry, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan;Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Wuerzburg, Wuerzburg, Germany

关键词: Cell proliferation;    Neuronal maturation;    Neural stem cells;    Methylphenidate;   

Others  :  820483
DOI  :  10.1186/2049-9256-1-5

 received in 2012-11-23, accepted in 2013-01-18,  发布年份 2013

【 摘 要 】

Background

The psychostimulant methylphenidate (MPH) is the first choice of drug treatment in Attention-Deficit/Hyperactivity Disorder (ADHD). Since therapy often begins at a time when the brain is still developing and the long-term consequences of MPH are still not fully clarified, we examined the influences of an acute treatment with MPH on the differentiation and proliferation of murine neural stem cells (mNSC).

Findings and conclusion

We found that MPH enhanced neuronal differentiation and inhibited neural proliferation.

【 授权许可】

   
2013 Bartl et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Biederman J, Faraone SV: Attention-deficit hyperactivity disorder. Lancet 2005, 366(9481):237-248.
• [2]Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA: The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007, 164(6):942-948.
• [3]Gunther T, Herpertz-Dahlmann B, Konrad K: Sex differences in attentional performance and their modulation by methylphenidate in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2010, 20(3):179-186.
• [4]Schubert I, Koster I, Lehmkuhl G: The changing prevalence of attention-deficit/hyperactivity disorder and methylphenidate prescriptions: a study of data from a random sample of insurees of the AOK Health Insurance Company in the German State of Hesse, 2000–2007. Dtsch Arztebl Int 2010, 107(36):615-621.
• [5]Han DD, Gu HH: Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol 2006, 6:6.
• [6]Bogle KE, Smith BH: Illicit methylphenidate use: a review of prevalence, availability, pharmacology, and consequences. Curr Drug Abuse Rev 2009, 2(2):157-176.
• [7]Lee TH, Lee CH, Kim IH, Yan BC, Park JH, Kwon SH, Park OK, Ahn JH, Cho JH, Won MH, Kim SK: Effects of ADHD therapeutic agents, methylphenidate and atomoxetine, on hippocampal neurogenesis in the adolescent mouse dentate gyrus. Neurosci Lett 2012, 524(2):84-88.
• [8]Lagace DC, Yee JK, Bolanos CA, Eisch AJ: Juvenile administration of methylphenidate attenuates adult hippocampal neurogenesis. Biol Psychiatry 2006, 60(10):1121-1130.
• [9]Tropepe V, Sibilia M, Ciruna BG, Rossant J, Wagner EF, van der Kooy D: Distinct neural stem cells proliferate in response to EGF and FGF in the developing mouse telencephalon. Dev Biol 1999, 208(1):166-188.
• [10]Onorati M, Camnasio S, Binetti M, Jung CB, Moretti A, Cattaneo E: Neuropotent self-renewing neural stem (NS) cells derived from mouse induced pluripotent stem (iPS) cells. Mol Cell Neurosci 2010, 43(3):287-295.
• [11]Bartl J, Link P, Schlosser C, Gerlach M, Schmitt A, Walitza S, Riederer P, Grunblatt E: Effects of methylphenidate: the cellular point of view. Atten Defic Hyperact Disord 2010, 2(4):225-232.
• [12]Vaidya CJ: Neurodevelopmental abnormalities in ADHD. Curr Top Behav Neurosci 2012, 9:49-66.
• [13]Seidman LJ, Valera EM, Makris N: Structural brain imaging of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005, 57(11):1263-1272.
• [14]Mostofsky SH, Rimrodt SL, Schafer JG, Boyce A, Goldberg MC, Pekar JJ, Denckla MB: Atypical motor and sensory cortex activation in attention-deficit/hyperactivity disorder: a functional magnetic resonance imaging study of simple sequential finger tapping. Biol Psychiatry 2006, 59(1):48-56.
• [15]Rubia K, Halari R, Christakou A, Taylor E: Impulsiveness as a timing disturbance: neurocognitive abnormalities in attention-deficit hyperactivity disorder during temporal processes and normalization with methylphenidate. Philos Trans R Soc Lond B Biol Sci 2009, 364(1525):1919-1931.
• [16]Castellanos FX, Lee PP, Sharp W, Jeffries NO, Greenstein DK, Clasen LS, Blumenthal JD, James RS, Ebens CL, Walter JM, Zijdenbos A, Evans AC, Giedd JN, Rapoport JL: Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder. JAMA 2002, 288(14):1740-1748.
• [17]Semrud-Clikeman M, Pliszka SR, Lancaster J, Liotti M: Volumetric MRI differences in treatment-naive vs chronically treated children with ADHD. Neurology 2006, 67(6):1023-1027.
• [18]Tye KM, Tye LD, Cone JJ, Hekkelman EF, Janak PH, Bonci A: Methylphenidate facilitates learning-induced amygdala plasticity. Nat Neurosci 2010, 13(4):475-481.